These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 22288465)

  • 21. Modulation effect of substantia nigra iron deposition and functional connectivity on putamen glucose metabolism in Parkinson's disease.
    Zang Z; Song T; Li J; Yan S; Nie B; Mei S; Ma J; Yang Y; Shan B; Zhang Y; Lu J
    Hum Brain Mapp; 2022 Aug; 43(12):3735-3744. PubMed ID: 35471638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease.
    Dexter DT; Wells FR; Lees AJ; Agid F; Agid Y; Jenner P; Marsden CD
    J Neurochem; 1989 Jun; 52(6):1830-6. PubMed ID: 2723638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum cholesterol and nigrostriatal R2* values in Parkinson's disease.
    Du G; Lewis MM; Shaffer ML; Chen H; Yang QX; Mailman RB; Huang X
    PLoS One; 2012; 7(4):e35397. PubMed ID: 22530017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of cerebral iron content in patients with Parkinson's disease by the susceptibility-weighted MRI.
    Wu SF; Zhu ZF; Kong Y; Zhang HP; Zhou GQ; Jiang QT; Meng XP
    Eur Rev Med Pharmacol Sci; 2014; 18(18):2605-8. PubMed ID: 25317792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence.
    Graham JM; Paley MN; Grünewald RA; Hoggard N; Griffiths PD
    Brain; 2000 Dec; 123 Pt 12():2423-31. PubMed ID: 11099445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transplanted Neural Stem Cells: Playing a Neuroprotective Role by Ceruloplasmin in the Substantia Nigra of PD Model Rats?
    Xiao JJ; Yin M; Wang ZJ; Wang XP
    Oxid Med Cell Longev; 2015; 2015():618631. PubMed ID: 26146528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impairment of Motor Function Correlates with Neurometabolite and Brain Iron Alterations in Parkinson's Disease.
    Pesch B; Casjens S; Woitalla D; Dharmadhikari S; Edmondson DA; Zella MAS; Lehnert M; Lotz A; Herrmann L; Muhlack S; Kraus P; Yeh CL; Glaubitz B; Schmidt-Wilcke T; Gold R; van Thriel C; Brüning T; Tönges L; Dydak U
    Cells; 2019 Jan; 8(2):. PubMed ID: 30699914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry.
    Pyatigorskaya N; Sharman M; Corvol JC; Valabregue R; Yahia-Cherif L; Poupon F; Cormier-Dequaire F; Siebner H; Klebe S; Vidailhet M; Brice A; Lehéricy S
    Mov Disord; 2015 Jul; 30(8):1077-84. PubMed ID: 26011561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nigral iron deposition in common tremor disorders.
    Homayoon N; Pirpamer L; Franthal S; Katschnig-Winter P; Kögl M; Seiler S; Wenzel K; Hofer E; Deutschmann H; Fazekas F; Langkammer C; Ropele S; Schmidt R; Schwingenschuh P
    Mov Disord; 2019 Jan; 34(1):129-132. PubMed ID: 30536988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.
    Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD
    Ann Neurol; 1994 Sep; 36(3):348-55. PubMed ID: 8080242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The whole-brain pattern of magnetic susceptibility perturbations in Parkinson's disease.
    Acosta-Cabronero J; Cardenas-Blanco A; Betts MJ; Butryn M; Valdes-Herrera JP; Galazky I; Nestor PJ
    Brain; 2017 Jan; 140(1):118-131. PubMed ID: 27836833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional relevance of ceruloplasmin mutations in Parkinson's disease.
    Hochstrasser H; Tomiuk J; Walter U; Behnke S; Spiegel J; Krüger R; Becker G; Riess O; Berg D
    FASEB J; 2005 Nov; 19(13):1851-3. PubMed ID: 16150804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
    Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
    Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease.
    Grolez G; Moreau C; Sablonnière B; Garçon G; Devedjian JC; Meguig S; Gelé P; Delmaire C; Bordet R; Defebvre L; Cabantchik IZ; Devos D
    BMC Neurol; 2015 May; 15():74. PubMed ID: 25943368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease.
    Gorell JM; Ordidge RJ; Brown GG; Deniau JC; Buderer NM; Helpern JA
    Neurology; 1995 Jun; 45(6):1138-43. PubMed ID: 7783878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ceruloplasmin in Parkinson's disease and the nonmotor symptoms.
    Zhao X; Shao Z; Zhang Y; Liu F; Liu Z; Liu Z
    Brain Behav; 2018 Jun; 8(6):e00995. PubMed ID: 29733522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma ceruloplasmin ferroxidase activity correlates with the nigral sonographic area in Parkinson's disease patients: a pilot study.
    Martínez-Hernández R; Montes S; Higuera-Calleja J; Yescas P; Boll MC; Diaz-Ruiz A; Rios C
    Neurochem Res; 2011 Nov; 36(11):2111-5. PubMed ID: 21706376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined Application of Quantitative Susceptibility Mapping and Diffusion Kurtosis Imaging Techniques to Investigate the Effect of Iron Deposition on Microstructural Changes in the Brain in Parkinson's Disease.
    Yang L; Cheng Y; Sun Y; Xuan Y; Niu J; Guan J; Rong Y; Jia Y; Zhuang Z; Yan G; Wu R
    Front Aging Neurosci; 2022; 14():792778. PubMed ID: 35370619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dentate nucleus iron deposition is a potential biomarker for tremor-dominant Parkinson's disease.
    He N; Huang P; Ling H; Langley J; Liu C; Ding B; Huang J; Xu H; Zhang Y; Zhang Z; Hu X; Chen S; Yan F
    NMR Biomed; 2017 Apr; 30(4):. PubMed ID: 27192177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis.
    Hirsch EC; Brandel JP; Galle P; Javoy-Agid F; Agid Y
    J Neurochem; 1991 Feb; 56(2):446-51. PubMed ID: 1988548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.